GEISTLICH PHARMA AG
Desconocido
MEFISTO: MEFISTO Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy
GEISTLICH PHARMA AG
participó en un
H2020:
H2020-NMBP-TR-IND-2018-2020
MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy k...
2019-03-05 - 2024-11-30 | Financiado
2019-03-05 - 2024-11-30 | Financiado
* No se disponen de datos de la empresa actual.